Tue, Jul 22, 2014, 6:33 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Ampio Pharmaceuticals, Inc. Message Board

  • racavalli racavalli Apr 3, 2013 3:40 PM Flag

    LARGE AMD and DME MARKETS

    The AMD and DME markets are very large and growing fast as the incidence of diabetes accelerates.

    Lucentis and Eylea have no competition yet, but if Optina is approved, their sales will plummet because Optina is a pill rather than a brutal injection directly into the eyeball and Optina works better because it actually repairs the leaking blood vessels.

    Optina has an extremely high probability of FDA approval because it has already passed safety and efficacy has already been demonstrated even though the numbers were small. Retina Today was impressed enough with the efficacy of Optina that they published a cover story called, "Oral Danazol For DME"

    If I were a Regeneron shareholder, I would be watching the Optina trial closely because it is very likely to cause great damage to Eylea and Eylea generates 100% of REGN's revenues.

    Sentiment: Strong Buy

 
AMPE
6.59+0.01(+0.15%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.